SCHEMBL15542002

SCHEMBL15542002

COc1ccccc1-c1ccccc1-c1nnnn1-c1ccccc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 19/20 1.00
ALDH1A1 P00352 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15542165 0.89 KCNN4 (1.00) KCNN4ALDH1A1
SCHEMBL15542319 0.89 KCNN4 (1.00) KCNN4
SCHEMBL15540963 0.89 KCNN4 (1.00) KCNN4ALDH1A1
SCHEMBL15542680 0.89 KCNN4 (1.00) KCNN4
SCHEMBL15542461 0.88 KCNN4 (1.00) KCNN4ALDH1A1
SCHEMBL16919487 0.86 KCNN4 (0.75) KCNN4ALDH1A1
SCHEMBL15542327 0.86 KCNN4 (1.00) KCNN4ALDH1A1
SCHEMBL4211677 0.80 KCNN4 (0.66) KCNN4ALDH1A1
SCHEMBL15542105 0.76 KCNN4 (1.00) KCNN4
SCHEMBL8653700 0.75 KCNN4 (0.60) KCNN4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867215-B1 TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA AS (DK) 2018-07-18 EP claimed
CN-104487427-B tetrazole derivatives and their use as potassium channel modulators 萨尼奥纳有限责任公司 2017-03-15 CN claimed
US-20150203458-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA APS (DK) 2015-07-23 US claimed
EP-2867215-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA APS (DK) 2015-05-06 EP claimed
WO-2014001363-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CLEVEXEL PHARMA (FR) 2014-01-03 WO claimed
EP-2867215-B1 TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA AS (DK) 2018-07-18 EP disclosed
CN-104487427-B tetrazole derivatives and their use as potassium channel modulators 萨尼奥纳有限责任公司 2017-03-15 CN disclosed
US-9556132-B2 Tetrazole derivatives and their use as potassium channel modulators SANIONA A/S (DK) 2017-01-31 US disclosed
US-9556132-B2 Tetrazole derivatives and their use as potassium channel modulators SANIONA A/S (DK) 2017-01-31 US disclosed
US-9556132-B2 Tetrazole derivatives and their use as potassium channel modulators SANIONA A/S (DK) 2017-01-31 US disclosed
US-20150203458-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA APS (DK) 2015-07-23 US disclosed
US-20150203458-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA APS (DK) 2015-07-23 US disclosed
US-20150203458-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA APS (DK) 2015-07-23 US disclosed
EP-2867215-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA APS (DK) 2015-05-06 EP disclosed
WO-2014001363-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CLEVEXEL PHARMA (FR) 2014-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203458-A1 NOVEL TETRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNN2, KCNA1 KCNN4 54/4885ALDH1A1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.